首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   1002936篇
  免费   56679篇
  国内免费   1626篇
耳鼻咽喉   12195篇
儿科学   33939篇
妇产科学   23929篇
基础医学   144259篇
口腔科学   24798篇
临床医学   84490篇
内科学   193747篇
皮肤病学   20688篇
神经病学   75977篇
特种医学   37860篇
外国民族医学   106篇
外科学   152035篇
综合类   18112篇
现状与发展   2篇
一般理论   185篇
预防医学   79541篇
眼科学   20962篇
药学   70790篇
  3篇
中国医学   3330篇
肿瘤学   64293篇
  2021年   8348篇
  2019年   8141篇
  2018年   33869篇
  2017年   26433篇
  2016年   30552篇
  2015年   10904篇
  2014年   14657篇
  2013年   21055篇
  2012年   34149篇
  2011年   50060篇
  2010年   35889篇
  2009年   27742篇
  2008年   46589篇
  2007年   51652篇
  2006年   27968篇
  2005年   28717篇
  2004年   29365篇
  2003年   29846篇
  2002年   26818篇
  2001年   39773篇
  2000年   40723篇
  1999年   33267篇
  1998年   9091篇
  1997年   7719篇
  1996年   7753篇
  1995年   7344篇
  1994年   6737篇
  1993年   6166篇
  1992年   24340篇
  1991年   24341篇
  1990年   23567篇
  1989年   23156篇
  1988年   20997篇
  1987年   20364篇
  1986年   19343篇
  1985年   18141篇
  1984年   13314篇
  1983年   11290篇
  1982年   6347篇
  1979年   12089篇
  1978年   8523篇
  1977年   7124篇
  1976年   6933篇
  1975年   7611篇
  1974年   8912篇
  1973年   8553篇
  1972年   8007篇
  1971年   7459篇
  1970年   7238篇
  1969年   6669篇
排序方式: 共有10000条查询结果,搜索用时 500 毫秒
51.
52.
53.

Objective

The “Centre Hospitalier Francois Dunan” is located on an isolated island and ensures patients care in hemodialysis thanks to telemedicine support. Many research studies have demonstrated the importance of hemodialysis fluids composition to reduce morbidity in patients on chronic hemodialysis. The aim of this study was to identify the risks inherent in the production of dialysis fluids in a particular context, in order to set up an improvement action plan to improve risk control on the production of dialysis fluids.

Methods

The risk analysis was conducted with the FMECA methodology (Failure Mode, Effects and Criticality Analysis) by a multi professional work group. Three types of risk have been reviewed: technical risks that may impact the production of hemodialysis fluids, health risks linked with chemical composition and health risks due to microbiological contamination of hemodialysis fluids.

Results

The work group, in close cooperation with the expert staff of the dialysis center providing telemedicine assistance, has developed an action plan in order to improve the control of the main risks brought to light by the risk analysis.

Conclusion

The exhaustive analysis of the risks and their prioritisation have permitted to establish a relevant action plan in this improving quality of dialysis fluids approach. The risk control of dialysis fluids is necessary for the security of dialysis sessions for patients, even more when these sessions are realized by telemedicine in Saint-Pierre-et-Miquelon.  相似文献   
54.
To evaluate the changes in alveolar contour after guided bone regeneration (GBR) with two different combinations of biomaterials in dehiscence defects arou  相似文献   
55.
56.
In the 6th Basic Plan for Long-Term Electricity Supply and Demand (6th BPE) for Korea, for the first time, the environmental costs of air pollution caused by oxides of sulfur (SOx), oxides of nitrogen (NOx), and particulate matters (PM) from power plants were estimated and included. However, several deficiencies in evaluating the environmental costs were found. In this study, (1) the validity of the environmental costs used in the 6th BPE was assessed, (2) a systematic approach was suggested and used to improve the environmental costs estimation, and (3) the sensitivity of the cost of generating electricity to the environmental costs by fuel type with the proposed approach was discussed. We found that the applied environmental costs used in the 6th BPE did not fully include the demographic characteristics of Korea. By applying more realistic parameter values, it was found that the newly estimated environmental cost was about 23 times higher than the cost estimated in the original 6th BPE for coal-fired power plants and about 1.5 times higher for liquefied natural gas (LNG)-fired power plants, suggesting that LNG-fired power plants are more economical if using more realistic environmental costs. Thus, it is critical to check the validity of parameter values when calculating environmental costs.  相似文献   
57.
58.
59.

Background

Refractory acute myeloid leukemia (AML) includes AML includes failure of disease to respond to standard induction chemotherapy, relapse within 6 months after first CR, and 2 or more relapses. The outcome of these patients is usually very poor; only a small proportion can be rescued by allogenic hematopoietic stem-cell transplantation (allo-HSCT). The aim of this study was to evaluate the efficacy and feasibility of allo-HSCT in patients with refractory AML.

Patients and Methods

We retrospectively analyzed the clinical outcome of 91 patients who were diagnosed with treatment-refractory AML at Hacettepe University Hospital between January 2002 and June 2018. Patients' disease status included refractory AML, defined as failure to respond to standard induction chemotherapy and relapse within 6 months after first complete remission.

Results

The median follow-up was 12 months (range, 0.5-184 months) for the entire group. Kaplan-Meier estimates of the 3-year overall survival for patients who underwent allo-HSCT and patients who received only salvage chemotherapy were 67% and 12%, respectively. Additionally, the Kaplan-Meier estimates of 5-year overall survival for patients who underwent allo-HSCT and patients who received only salvage chemotherapy were 44% and 4%, respectively (P < .001). Complete remission was obtained in 25 patients (83.3%) who underwent allo-HSCT; however, the disease of only 3 patients (3.8%) exhibited complete response after salvage chemotherapy.

Conclusion

Allo-HSCT is still the best-known treatment option with curative potential in patients with treatment-refractory AML. Therefore, all efforts should be made in an attempt to find a suitable matched donor in order to perform allo-HSCT.  相似文献   
60.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号